Do you include gemtuzumab ozogamicin for any of your newly diagnosed AML patients who are candidates for 7+3 induction chemotherapy?

Yes, I regularly add gemtuzumab ozogamicin (3 mg/m2 IV days 1, 4 and 7) to 7+3 (daunorubicin dose should be 60 mg/m2 IV days 1-3) in newly diagnosed AML in the following patient groups based on the ALFA-0701 data (Castaigne, Lancet 2012):

1) Favorable/Intermediate-risk cytogenetics- subset analyses with gemtuzumab have shown that there is no benefit in adverse-risk disease. I would recommend all AML patients have risk stratification with at least cytogenetics prior to induction therapy if stable and able to wait since treatment regimens differ based on cytogenetic risk.

2) 50-70 years- we occasionally add this to 7+3 in patients younger than 50 years with favorable or intermediate-risk disease but this trial was specifically done in those 5...